# Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

> **NCT04179162** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 54 (actual)

## Conditions studied

- Non-Muscle Invasive Bladder Cancer (NMIBC)

## Interventions

- **DRUG:** Bacillus Calmette-Guérin (BCG)
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT04179162
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-22
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04179162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04179162, "Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04179162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*